Michelle Tew

Ms. Michelle Tew

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2016 in Australian Health Review
Verified
Journal Article
Open access
PDF file
MTMichelle Tew
Michelle Tew
KDKim Dalziel
Kim Dalziel
DPDennis Petrie
Dennis Petrie
PCPhilip M. Clarke
Philip M. Clarke
Objective: The aim of the present study was to quantify and understand the utilisation of linked hospital data for research purposes across Australia over the past two decades. Methods: A systematic review was undertaken guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 checklist. Medline OVID, PsycINFO, Embase, EconLit and Scopus were searched to identify articles published from 1946 to December 2014. Information on publication year, state(s) involved, type of data linkage, disease area and purpose was extracted. Results: The search identified 3314 articles, of which 606 were included; these generated 629 records of hospital data linkage use across all Australian states and territories. The major contributions were from Western Australia (WA; 51%) and New South Wales (NSW; 32%) with the remaining states and territories having significantly fewer publications (total contribution only 17%). WA’s contribution resulted from a steady increase from the late 1990s, whereas NSW’s contribution is mostly from a rapid increase from 2010. Current data linkage is primarily used in epidemiological research (73%). Conclusion: More than 80% of publications were from WA and NSW, whereas other states significantly lag behind. The observable growth in these two states clearly demonstrates the underutilised opportunities for data linkage to add value in health services research in the other states. What is known about the topic?: Linking administrative hospital data to other data has the potential to be a cost-effective method to significantly improve health policy. Over the past two decades, Australia has made significant investments in improving its data linkage capabilities. However, several articles have highlighted the many barriers involved in using linked hospital data. What does this paper add?: This paper quantitatively evaluates the performance across all Australian states in terms of the use of their administrative hospital data for research purposes. The performance of states varies considerably, with WA and NSW the clear stand-out performers and limited outputs currently seen for the other Australian states and territories. What are the implications for practitioners?: Given the significant investments made into data linkage, it is important to continue to evaluate and monitor the performance of the states in terms of translating this investment into outputs. Where the outputs do not match the investment, it is important to identify and overcome those barriers limiting the gains from this investment. More generally, there is a need to think about how we improve the effective and efficient use of data linkage investments in Australia.

10 July 2020 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
MTMichelle Tew
Michelle Tew
KDKim Dalziel
Kim Dalziel
PCPhilip Clarke
Philip Clarke
ASAnne Smith
Anne Smith
Peter ChoongPeter Choong
Peter Choong
MDMichelle Maree Dowsey
Michelle Maree Dowsey

8 August 2022 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
LSLeonard L. Shan
Leonard L. Shan
LYLinda S. Yang
Linda S. Yang
MTMichelle Tew
Michelle Tew
MWMark J. Westcott
Mark J. Westcott
TSTim D. Spelman
Tim D. Spelman
ADAlun H. Davies
Alun H. Davies

4 March 2023 in Trials
Verified
Journal Article
Open access
PDF file
MTMichelle Tew
Michelle Tew
MCMax Catchpool
Max Catchpool
JFJohn Furler
John Furler
KRKatie De La Rue
Katie De La Rue
PCPhilip Clarke
Philip Clarke
KDKim Dalziel
Kim Dalziel
Background: Recruitment of participants is crucial to the success of randomised control trials (RCTs) but can be challenging and expensive. Current research on trial efficiency is often focused at the patient-level with an emphasis on effective recruitment strategies. Less is known about selection of study sites to optimise recruitment. We examine site-level factors that are associated with patient recruitment and cost efficiency using data from an RCT conducted across 25 general practices (GP) in Victoria, Australia. Methods: Data on number of participants screened, excluded, eligible, recruited, and randomised from each study site were extracted from a clinical trial. Details regarding site characteristics, recruitment practices, and staff time commitment were collected using a three-part survey. The key outcomes assessed were recruitment efficiency (ratio of screened to randomised), average time, and cost for each participant recruited and randomised. To identify practice-level factors associated with efficient recruitment and lower cost, outcomes were dichotomised (25th percentile vs others) and each practice-level factor assessed against the outcomes to determine its association. Results: Across 25 GP study sites, 1968 participants were screened of which 299 (15.2%) were recruited and randomised. The mean recruitment efficiency was 7.2, varying from 1.4 to 19.8 across sites. The strongest factor associated with efficiency was assigning clinical staff to identify potential participants (57.14% vs. 22.2%). The more efficient sites were smaller practices and were more likely to be rural locations and in areas of lower socioeconomic status. The average time used for recruitment was 3.7 h (SD2.4) per patient randomised. The mean cost per patient randomised was $277 (SD161), and this varied from $74 to $797 across sites. The sites identified with the 25% lowest recruitment cost (n = 7) were more experienced in research participation and had high levels of nurse and/or administrative support. Conclusion: Despite the small sample size, this study quantified the time and cost used to recruit patients and provides helpful indications of site-level characteristics that can help improve feasibility and efficiency of conducting RCT in GP settings. Characteristics indicative of high levels of support for research and rural practices, which often tends to be overlooked, were observed to be more efficient in recruiting.

11 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMichelle Tew
Michelle Tew
KDKim Dalziel
Kim Dalziel
KTKarin Thursky
Karin Thursky
MKMurray Krahn
Murray Krahn
LALusine Abrahamyan
Lusine Abrahamyan
PCPhilip Clarke
Philip Clarke
Background: Cancer patients are at significant risk of developing sepsis due to underlying malignancy and necessary treatments. Little is known about the economic burden of sepsis in this high-risk population. We estimate the short- and long-term healthcare costs of care of cancer patients with and without sepsis using individual-level linked-administrative data. Methods: We conducted a population-based matched cohort study of cancer patients aged ≥18, diagnosed between 2010 and 2017. Cases were identified if diagnosed with sepsis during the study period, and were matched 1:1 by age, sex, cancer type and other variables to controls without sepsis. Mean costs (2018 Canadian dollars) for patients with and without sepsis up to 5 years were estimated adjusted using survival probabilities at partitioned intervals. We estimated excess cost associated with sepsis presented as a cost difference between the two cohorts. Haematological and solid cancers were analysed separately. Results: 77,483 cancer patients with sepsis were identified and matched. 64.3% of the cohort were aged ≥65, 46.3% female and 17.8% with haematological malignancies. Among solid tumour patients, the excess cost of care among patients who developed sepsis was $29,081 (95%CI, $28,404-$29,757) in the first year, rising to $60,714 (95%CI, $59,729-$61,698) over 5 years. This was higher for haematology patients; $46,154 (95%CI, $45,505-$46,804) in year 1, increasing to $75,931 (95%CI, $74,895-$76,968). Conclusions: Sepsis imposes substantial economic burden and can result in a doubling of cancer care costs, particularly during the first year of cancer diagnosis. These estimates are helpful in improving our understanding of burden of sepsis along the cancer pathway and to deploy targeted strategies to alleviate this burden.

2 December 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MTMichelle Tew
Michelle Tew
RLRichard De Abreu Lourenco
Richard De Abreu Lourenco
JGJoshua Robert Gordon
Joshua Robert Gordon
KTKarin A. Thursky
Karin A. Thursky
MSMonica A. Slavin
Monica A. Slavin
GHGabrielle M. Haeusler
Gabrielle M. Haeusler